- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07931053
Use of mHealth Application and Education to Increase Appropriateness of Thromboprophylaxis in Patients With Cancer
mHealth-supported Education Improves Thromboprophylaxis Appropriateness in Solid Tumors
Doctors will use a mHealth application to evaluate the risk of thrombosis and bleeding in patients with cancer.
Study Overview
Status
Intervention / Treatment
Detailed Description
This information will be shared with the patients to make an informed decision of using low molecular weight prophylaxis with heparin in case of high risk thrombosis a low-moderate risk of bleeding
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Alicante
-
Villajoyosa, Alicante, Spain, 03570
- Hospital Marina Baixa
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age 18 years or older, and
- Recent diagnosis of a solid tumor or disease progression after partial or complete remission, and.
- Starting a new course of systemic anticancer therapy (chemotherapy, targeted therapy, hormone therapy, or immunotherapy) planned for at least 3 months
Exclusion Criteria:
- High risk of bleeding (e.g., advanced liver disease with coagulopathy), or
- Life expectancy under 3 months, or
- Hematologic malignancies, or
- Estimated glomerular filtration rate below 30 mL/min/1.73 m², or
- Platelet count below 50,000/mm³, or
- Body weight below 40 kg, or
- Current anticoagulant use.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Health Services Research
- Allocation: Non-Randomized
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
No Intervention: Control group (preintervention)
Inclusion criteria:
Exclusion criteria:
In the preintervention period, we reviewed the electronic medical records of patients with a recent cancer diagnosis who were seen between January and June 2024. |
|
|
Active Comparator: postintervention
After using the mHealth application, the treating physician made the final decision regarding use of thromboprophylaxis after considering risk of thromboembolic disease, bleeding risk, renal function, drug interactions, and patient preferences. Postintervention period. For patients with cancer seen between January and June 2025, we collected the same variables from the electronic medical records as in the preintervention period. We selected the same calendar months to control for seasonality and enhance comparability between periods |
Physicians from the Internal Medicine and Oncology divisions attended a 2-hour session reviewing current guidelines for thromboprophylaxis in patients with cancer, followed by training on the mHealth TEVAPP application. TEVAPP is a web-based calculator of venous thromboembolism (VTE) risk scores for patients with cancer, developed by the Spanish Society of Medical Oncology (SEOM) (Spain; https://tevapp.es/; accessed December 15, 2024). The application was used to support clinical decision-making by integrating available clinical, laboratory, and treatment information at the initial visit before the initiation of a new systemic regimen. TEVAPP is a web-based calculator of VTE risk scores for patients with cancer, developed by SEOM (Spain; https://tevapp.es/; accessed December 15, 2024). It was used to support clinical decisions by integrating available clinical, laboratory, and treatment information at the initial visit before a new systemic regimen |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Proprtion of patients with appropriate thromboprophylaxis use
Time Frame: From first visit to oncology clinic up to three month of follow up
|
The primary outcome was the proportion of patients with appropriate prescription of thromboprophylaxis from the first medical oncology visit in the pre- and postintervention periods. The appropriateness of thromboprophylaxis was determined according to clinical practice guideline recommendations. Thromboprophylaxis was considered appropriate when weight-adjusted enoxaparin was prescribed for patients at intermediate or high thrombotic risk (6-month VTE probability >8%) and low bleeding risk, in the absence of other contraindications. Low bleeding risk was defined as an IMPROVE score <7 for patients hospitalized within the previous 30 days, or a Hokusai score <3 for nonhospitalized patients. In the version of TEVAPP used, the latter corresponded to fewer than 60% of bleeding risk factors. Withholding thromboprophylaxis was considered appropriate for patients at low thrombotic risk or with contraindications to anticoagulation. |
From first visit to oncology clinic up to three month of follow up
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Incidence of venous thromboembolic disease
Time Frame: From first visit the the Oncology Clinic up to three months of follow-up
|
We compared the incidence of VTE disease in the pre- and postintervention periods. VTE is suspected based on clinical symptoms and signs and confirmed with objective testing. The diagnostic approach includes assessment of pretest clinical probability, selective D-dimer testing, and imaging. Suspected DVT: Clinical probability is estimated using the 2-level Wells score. Patients with a likely score (≥2 points) should undergo proximal leg-vein compression ultrasonography, preferably with Doppler assessment; D-dimer may be used selectively when ultrasound is negative or clinical probability is low. Suspected PE: Clinical probability is estimated using a validated score such as the Wells score. Definitive diagnosis is usually made with computed tomography pulmonary angiography (CTPA); a ventilation-pe |
From first visit the the Oncology Clinic up to three months of follow-up
|
|
Incidence of bleeding
Time Frame: From first visit the the Oncology Clinic up to three months of follow-up
|
We compared the bleeding events in the pre- and postintervention periods classified according to the International Society on Thrombosis and Haemostasis (ISTH) criteria. Major bleeding was defined as fatal bleeding, symptomatic bleeding in a critical site or organ (intracranial, intraspinal, intraocular, retroperitoneal, intra-articular, or pericardial bleeding, or intramuscular bleeding with compartment syndrome), or bleeding associated with a hemoglobin decrease of ≥2 g/dL or transfusion of ≥2 units of whole blood or packed red blood cells. Clinically relevant non-major bleeding was defined as overt bleeding not meeting major bleeding criteria but requiring hospitalization, medical or surgical intervention, or interruption or modification of anticoagulant therapy |
From first visit the the Oncology Clinic up to three months of follow-up
|
|
Incidence of death
Time Frame: From first visit the the Oncology Clinic up to three months of follow-up
|
We compared all-cause mortality in the pre- and postintervention periods. All-cause mortality was defined as death from any cause occurring during the study follow-up period. |
From first visit the the Oncology Clinic up to three months of follow-up
|
Collaborators and Investigators
Investigators
- Principal Investigator: Javier Ena, MD, Hospital Marina Baixa
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Univeridad Miguel Hernandez
- UGP-24-212 (Other Grant/Funding Number: Fundación Eugenio Rodriguez Pascual)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Upon reasonable request with patient de-identification
IPD Sharing Time Frame
October 2026, to October 2027
IPD Sharing Access Criteria
Javier Ena, MD. Personal computer
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.